APA (7th ed.) Citation

Muntoni, F., Byrne, B. J., McMillan, H. J., Ryan, M. M., Wong, B. L., Dukart, J., . . . Gokemeijer, J. (2024). The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy. Neurology & Therapy, 13(1), 183. https://doi.org/10.1007/s40120-023-00570-w

Chicago Style (17th ed.) Citation

Muntoni, Francesco, et al. "The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy." Neurology & Therapy 13, no. 1 (2024): 183. https://doi.org/10.1007/s40120-023-00570-w.

MLA (9th ed.) Citation

Muntoni, Francesco, et al. "The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy." Neurology & Therapy, vol. 13, no. 1, 2024, p. 183, https://doi.org/10.1007/s40120-023-00570-w.